source
- Novartis' Lp(a) drug pelacarsen fails to cut heart attack or stroke risk in phase 3 trialNovartis, in partnership with Ionis, completed the phase 3 Lp(a)Horizon trial of pelacarsen, an antisense oligonucleotide designed to lower lipoprotein(a) levels. The study enrolled more than 8,30…
- Truist sees biotech rebound as M&A hits $136B and XBI climbs 34% in H1Truist Securities says the biotech sector is regaining momentum after a prolonged post‑pandemic slowdown, driven by rising merger activity, returning venture capital and easing policy risks. The S…